Short Interest in ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) Grows By 5.4%

ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) was the recipient of a significant increase in short interest during the month of October. As of October 31st, there was short interest totalling 2,160,000 shares, an increase of 5.4% from the October 15th total of 2,050,000 shares. Based on an average daily trading volume, of 310,500 shares, the days-to-cover ratio is currently 7.0 days.

ANI Pharmaceuticals Stock Down 4.0 %

ANIP stock opened at $56.58 on Monday. The stock has a market cap of $1.19 billion, a PE ratio of -102.87 and a beta of 0.71. The firm’s 50-day simple moving average is $58.40 and its 200 day simple moving average is $61.28. ANI Pharmaceuticals has a fifty-two week low of $48.20 and a fifty-two week high of $70.81. The company has a quick ratio of 1.97, a current ratio of 2.74 and a debt-to-equity ratio of 1.52.

ANI Pharmaceuticals (NASDAQ:ANIP) last announced its quarterly earnings results on Friday, November 8th. The specialty pharmaceutical company reported $1.34 EPS for the quarter, beating the consensus estimate of $1.09 by $0.25. The company had revenue of $148.30 million for the quarter, compared to analyst estimates of $144.37 million. ANI Pharmaceuticals had a negative net margin of 1.28% and a positive return on equity of 15.87%. ANI Pharmaceuticals’s revenue was up 12.5% compared to the same quarter last year. During the same quarter last year, the business earned $1.05 earnings per share. As a group, sell-side analysts predict that ANI Pharmaceuticals will post 3.5 EPS for the current year.

Institutional Inflows and Outflows

Institutional investors have recently added to or reduced their stakes in the business. Innealta Capital LLC acquired a new position in shares of ANI Pharmaceuticals during the second quarter valued at $65,000. Ridgewood Investments LLC acquired a new position in ANI Pharmaceuticals during the 2nd quarter valued at about $85,000. SG Americas Securities LLC bought a new stake in shares of ANI Pharmaceuticals during the 1st quarter worth about $106,000. Zurcher Kantonalbank Zurich Cantonalbank raised its position in shares of ANI Pharmaceuticals by 24.2% during the 3rd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 2,971 shares of the specialty pharmaceutical company’s stock worth $177,000 after buying an additional 579 shares in the last quarter. Finally, O Shaughnessy Asset Management LLC acquired a new stake in shares of ANI Pharmaceuticals in the 1st quarter worth approximately $218,000. Institutional investors and hedge funds own 76.05% of the company’s stock.

Analyst Upgrades and Downgrades

Several research analysts have recently commented on the company. Truist Financial lifted their target price on ANI Pharmaceuticals from $60.00 to $62.00 and gave the stock a “hold” rating in a research report on Tuesday, October 22nd. StockNews.com lowered shares of ANI Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Saturday, September 7th. Raymond James raised their price target on shares of ANI Pharmaceuticals from $81.00 to $83.00 and gave the stock an “outperform” rating in a research report on Wednesday, September 18th. Piper Sandler began coverage on shares of ANI Pharmaceuticals in a research report on Friday, October 11th. They set an “overweight” rating and a $68.00 price objective for the company. Finally, HC Wainwright reissued a “buy” rating and issued a $94.00 target price on shares of ANI Pharmaceuticals in a report on Monday, November 11th. Two equities research analysts have rated the stock with a hold rating and five have assigned a buy rating to the stock. According to data from MarketBeat.com, ANI Pharmaceuticals has an average rating of “Moderate Buy” and an average price target of $77.33.

About ANI Pharmaceuticals

ANI Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products.